Advertisement

Gene Therapy

  • Barb Thorne
  • Ryan Takeya
  • Francesca Vitelli
  • Xin Swanson
Chapter
Part of the Advances in Biochemical Engineering/Biotechnology book series (ABE, volume 165)

Abstract

Gene therapy refers to a rapidly growing field of medicine in which genes are introduced into the body to treat or prevent diseases. Although a variety of methods can be used to deliver the genetic materials into the target cells and tissues, modified viral vectors represent one of the more common delivery routes because of its transduction efficiency for therapeutic genes. Since the introduction of gene therapy concept in the 1970s, the field has advanced considerably with notable clinical successes being demonstrated in many clinical indications in which no standard treatment options are currently available. It is anticipated that the clinical success the field observed in recent years can drive requirements for more scalable, robust, cost effective, and regulatory-compliant manufacturing processes. This review provides a brief overview of the current manufacturing technologies for viral vectors production, drawing attention to the common upstream and downstream production process platform that is applicable across various classes of viral vectors and their unique manufacturing challenges as compared to other biologics. In addition, a case study of an industry-scale cGMP production of an AAV-based gene therapy product performed at 2,000 L-scale is presented. The experience and lessons learned from this largest viral gene therapy vector production run conducted to date as discussed and highlighted in this review should contribute to future development of commercial viable scalable processes for vial gene therapies.

Keywords

AAV Gene therapy Large-scale production Viral vector 

References

  1. 1.
    Wilson JM (2009) Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 96(4):151–157CrossRefPubMedGoogle Scholar
  2. 2.
    Hacein-Bey-Abina S et al. (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118(9):3132–3142PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Kaufmann KB et al. (2013) Gene therapy on the move. EMBO Mol Med 5(11):1642–1661PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Brimble MA et al. (2016) New and improved AAVenues: current status of hemophilia B gene therapy. Expert Opin Biol Ther 16(1):79–92CrossRefPubMedGoogle Scholar
  5. 5.
    Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4(5):346–358CrossRefPubMedGoogle Scholar
  6. 6.
    Templeton NS (2015) Gene and cell therapy, 4th edn. CRC Press, Boca RatonGoogle Scholar
  7. 7.
    Wold WS, Toth K (2013) Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13(6):421–433PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Shen CF et al. (2012) Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3). Vaccine 30(2):300–306CrossRefPubMedGoogle Scholar
  9. 9.
    Vellinga J et al. (2014) Challenges in manufacturing adenoviral vectors for global vaccine product deployment. Hum Gene Ther 25(4):318–327CrossRefPubMedGoogle Scholar
  10. 10.
    Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7(1):33–40CrossRefPubMedGoogle Scholar
  11. 11.
    Dormond E, Perrier M, Kamen A (2009) From the first to the third generation adenoviral vector: what parameters are governing the production yield? Biotechnol Adv 27(2):133–144CrossRefPubMedGoogle Scholar
  12. 12.
    Bartel M, Schaffer D, Buning H (2011) Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front Microbiol 2:204PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Lisowski L et al. (2014) Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506(7488):382–386CrossRefPubMedGoogle Scholar
  14. 14.
    Wright JF (2008) Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 15(11):840–848CrossRefPubMedGoogle Scholar
  15. 15.
    Grieger JC, Soltys SM, Samulski RJ (2015) Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol Ther 24:287PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Emmerling VV et al. (2015) Rational plasmid design and bioprocess optimization to enhance recombinant adeno-associated virus (AAV) productivity in mammalian cells. Biotechnol J 11:290CrossRefPubMedGoogle Scholar
  17. 17.
    Xiao X, Li J, Samulski RJ (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72(3):2224–2232PubMedCentralPubMedGoogle Scholar
  18. 18.
    Clement N, Knop DR, Byrne BJ (2009) Large-scale adeno-associated viral vector production using a herpes virus-based system enables manufacturing for clinical studies. Hum Gene Ther 20(8):796–806PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Ye GJ et al. (2014) Herpes simplex virus clearance during purification of a recombinant adeno-associated virus serotype 1 vector. Hum Gene Ther Clin Dev 25(4):212–217CrossRefPubMedGoogle Scholar
  20. 20.
    Booth MJ et al. (2004) Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Ther 11(10):829–837CrossRefPubMedGoogle Scholar
  21. 21.
    Thorne BA, Takeya RK, Peluso RW (2009) Manufacturing recombinant adeno-associated viral vectors from producer cell clones. Hum Gene Ther 20(7):707–714CrossRefPubMedGoogle Scholar
  22. 22.
    Clark KR et al. (1995) Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 6(10):1329–1341CrossRefPubMedGoogle Scholar
  23. 23.
    Gao GP et al. (2002) Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol Ther 5(5 Pt 1):644–649CrossRefPubMedGoogle Scholar
  24. 24.
    Farson D et al. (2004) Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J Gene Med 6(12):1369–1381CrossRefPubMedGoogle Scholar
  25. 25.
    Urabe M, Ding C, Kotin RM (2002) Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 13(16):1935–1943CrossRefPubMedGoogle Scholar
  26. 26.
    Chen H (2008) Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells. Mol Ther 16(5):924–930CrossRefPubMedGoogle Scholar
  27. 27.
    Mietzsch M et al. (2014) OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy. Hum Gene Ther 25(3):212–222CrossRefPubMedGoogle Scholar
  28. 28.
    Aucoin MG, Perrier M, Kamen AA (2006) Production of adeno-associated viral vectors in insect cells using triple infection: optimization of baculovirus concentration ratios. Biotechnol Bioeng 95(6):1081–1092CrossRefPubMedGoogle Scholar
  29. 29.
    Galibert L, Merten OW (2011) Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases. J Invertebr Pathol 107(Suppl):S80–S93CrossRefPubMedGoogle Scholar
  30. 30.
    Segura MM, Kamen A, Garnier A (2006) Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol Adv 24(3):321–337CrossRefPubMedGoogle Scholar
  31. 31.
    Carmo M et al. (2006) Relationship between retroviral vector membrane and vector stability. J Gen Virol 87(Pt 5):1349–1356CrossRefPubMedGoogle Scholar
  32. 32.
    Carmo M et al. (2008) From retroviral vector production to gene transfer: spontaneous inactivation is caused by loss of reverse transcription capacity. J Gene Med 10(4):383–391CrossRefPubMedGoogle Scholar
  33. 33.
    Zufferey R et al. (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72(12):9873–9880PubMedCentralPubMedGoogle Scholar
  34. 34.
    Cronin J, Zhang XY, Reiser J (2005) Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 5(4):387–398PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Segura MM et al. (2013) New developments in lentiviral vector design, production and purification. Expert Opin Biol Ther 13(7):987–1011CrossRefPubMedGoogle Scholar
  36. 36.
    Rodrigues A, Alves PM, Coroadinha A (2011) Production of retroviral and lentiviral gene therapy vectors: challenges in the manufacturing of lipid enveloped virus. In: Xu K (ed) Viral gene therapy. InTech, RijekaGoogle Scholar
  37. 37.
    Farson D et al. (2001) A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther 12(8):981–997CrossRefPubMedGoogle Scholar
  38. 38.
    Ni Y et al. (2005) Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J Gene Med 7(6):818–834CrossRefPubMedGoogle Scholar
  39. 39.
    Broussau S et al. (2008) Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther 16(3):500–507CrossRefPubMedGoogle Scholar
  40. 40.
    Sanber KS et al. (2015) Construction of stable packaging cell lines for clinical lentiviral vector production. Sci Rep 5:9021PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Throm RE et al. (2009) Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113(21):5104–5110PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Schweizer M, Merten OW (2010) Large-scale production means for the manufacturing of lentiviral vectors. Curr Gene Ther 10(6):474–486CrossRefPubMedGoogle Scholar
  43. 43.
    Rodrigues AF et al. (2015) Single-step cloning-screening method: a new tool for developing and studying high-titer viral vector producer cells. Gene Ther 22(9):685–695CrossRefPubMedGoogle Scholar
  44. 44.
    Lim F (2013) HSV-1 as a model for emerging gene delivery vehicles. ISRN Virol 2013:12Google Scholar
  45. 45.
    Manservigi R, Argnani R, Marconi P (2010) HSV recombinant vectors for gene therapy. Open Virol J 4:123–156PubMedCentralPubMedGoogle Scholar
  46. 46.
    Bell JC (2012) The virus that came in from the cold. Sci Transl Med 4(138):138fs17CrossRefPubMedGoogle Scholar
  47. 47.
    Langfield KK et al. (2011) Manufacture of measles viruses. Methods Mol Biol 737:345–366CrossRefPubMedGoogle Scholar
  48. 48.
    Dimond PF (2013) Flexibility in biopharmaceutical manufacturing capacity: single-use bioreactors are changing the biomolecular production landscape. Genetic Engineering and Biotechnology News, New RochelleGoogle Scholar
  49. 49.
    Shukla AA, Gottschalk U (2013) Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol 31(3):147–154CrossRefPubMedGoogle Scholar
  50. 50.
    Lennaertz A et al. (2013) Viral vector production in the integrity iCELLis single-use fixed-bed bioreactor, from bench-scale to industrial scale. BMC Proc 7(Suppl 6):p59PubMedCentralCrossRefGoogle Scholar
  51. 51.
    Peng Z (2004) The genesis of gendicine: the story behind the first gene therapy. Biopharm Int 17(5):42–49Google Scholar
  52. 52.
    van der Loo JC et al. (2012) Scale-up and manufacturing of clinical-grade self-inactivating gamma-retroviral vectors by transient transfection. Gene Ther 19(3):246–254CrossRefPubMedGoogle Scholar
  53. 53.
    Fernandes P et al. (2013) Bioprocess development for canine adenovirus type 2 vectors. Gene Ther 20(4):353–360CrossRefPubMedGoogle Scholar
  54. 54.
    Nadeau I, Kamen A (2003) Production of adenovirus vector for gene therapy. Biotechnol Adv 20(7-8):475–489CrossRefPubMedGoogle Scholar
  55. 55.
    Silva AC et al. (2015) Human amniocyte-derived cells are a promising cell host for adenoviral vector production under serum-free conditions. Biotechnol J 10(5):760–771CrossRefPubMedGoogle Scholar
  56. 56.
    Cecchini S, Virag T, Kotin RM (2011) Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures. Hum Gene Ther 22(8):1021–1030PubMedCentralCrossRefPubMedGoogle Scholar
  57. 57.
    Segura MM et al. (2007) Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol Bioeng 98(4):789–799CrossRefPubMedGoogle Scholar
  58. 58.
    van der Loo JC, Wright JF (2015) Progress and challenges in viral vector manufacturing. Hum Mol Genet 25:R42PubMedCentralPubMedGoogle Scholar
  59. 59.
    Merten O-W, Gaillet B Viral vectors for gene therapy and gene modification approaches. Biochem Eng J 108:98CrossRefGoogle Scholar
  60. 60.
    Durocher Y, Perret S, Kamen A (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30(2):E9PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Jordan M, Schallhorn A, Wurm FM (1996) Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 24(4):596–601PubMedCentralCrossRefPubMedGoogle Scholar
  62. 62.
    Durocher Y et al. (2007) Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. J Virol Methods 144(1–2):32–40CrossRefPubMedGoogle Scholar
  63. 63.
    Huang X et al. (2013) AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications. J Virol Methods 193(2):270–277PubMedCentralCrossRefPubMedGoogle Scholar
  64. 64.
    Witting SR et al. (2012) Efficient large volume lentiviral vector production using flow electroporation. Hum Gene Ther 23(2):243–249CrossRefPubMedGoogle Scholar
  65. 65.
    Pear WS et al. (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90(18):8392–8396PubMedCentralCrossRefPubMedGoogle Scholar
  66. 66.
    Girard A, Verhoeyen E (2015) Lentiviral vectors design and applications. In: Templeton NS (ed) Gene and cell therapy, 4th edn. CRC Press, Boca RatonCrossRefGoogle Scholar
  67. 67.
    Lusky M (2005) Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther 16(3):281–291CrossRefPubMedGoogle Scholar
  68. 68.
    Lesch HP et al. (2008) Generation of lentivirus vectors using recombinant baculoviruses. Gene Ther 15(18):1280–1286CrossRefPubMedGoogle Scholar
  69. 69.
    Mietzsch M et al. (2015) OneBac 2.0: Sf9 cell lines for production of AAV5 vectors with enhanced infectivity and minimal encapsidation of foreign DNA. Hum Gene Ther 26(10):688–697PubMedCentralCrossRefPubMedGoogle Scholar
  70. 70.
    Smith RH, Levy JR, Kotin RM (2009) A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 17(11):1888–1896PubMedCentralCrossRefPubMedGoogle Scholar
  71. 71.
    Burnett JR, Hooper AJ (2009) Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Curr Opin Mol Ther 11(6):681–691PubMedGoogle Scholar
  72. 72.
    Rueda P et al. (2000) Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine 19(7–8):726–734CrossRefPubMedGoogle Scholar
  73. 73.
    Yuan Z et al. (2011) A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes. Hum Gene Ther 22(5):613–624CrossRefPubMedGoogle Scholar
  74. 74.
    Gao GP et al. (1998) High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 9(16):2353–2362CrossRefPubMedGoogle Scholar
  75. 75.
    Thorne BA et al. (2008) Characterizing clearance of helper adenovirus by a clinical rAAV1 manufacturing process. Biologicals 36(1):7–18CrossRefPubMedGoogle Scholar
  76. 76.
    Rodrigues T et al. (2007) Purification of retroviral vectors for clinical application: biological implications and technological challenges. J Biotechnol 127(3):520–541CrossRefPubMedGoogle Scholar
  77. 77.
    Hollyman D et al. (2009) Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 32(2):169–180PubMedCentralCrossRefPubMedGoogle Scholar
  78. 78.
    Segura MM, Kamen AA, Garnier A (2011) Overview of current scalable methods for purification of viral vectors. Methods Mol Biol 737:89–116CrossRefPubMedGoogle Scholar
  79. 79.
    Merten OW et al. (2011) Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 22(3):343–356CrossRefPubMedGoogle Scholar
  80. 80.
    EMA, (Draft) Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products 2015Google Scholar
  81. 81.
    EP, European Pharmacopoeia Chapter 5.14 Gene transfer medicinal products for human use. 2013Google Scholar
  82. 82.
    Ausubel LJ et al. (2012) Production of CGMP-grade lentiviral vectors. Bioprocess Int 10(2):32–43PubMedCentralPubMedGoogle Scholar
  83. 83.
    Bandeira V et al. (2012) Downstream processing of lentiviral vectors: releasing bottlenecks. Hum Gene Ther Methods 23(4):255–263CrossRefPubMedGoogle Scholar
  84. 84.
    Vicente T et al. (2009) Purification of recombinant baculoviruses for gene therapy using membrane processes. Gene Ther 16(6):766–775CrossRefPubMedGoogle Scholar
  85. 85.
    van Reis R, Zydney A (2007) Bioprocess membrane technology. J Membr Sci 297:16–50CrossRefGoogle Scholar
  86. 86.
    McNally DJ et al. (2014) Optimised concentration and purification of retroviruses using membrane chromatography. J Chromatogr A 1340:24–32PubMedCentralCrossRefPubMedGoogle Scholar
  87. 87.
    Riske F et al. (2013) Development of a platform process for adenovirus purification that removes human SET and nucleolin and provides high purity vector for gene delivery. Biotechnol Bioeng 110(3):848–856CrossRefPubMedGoogle Scholar
  88. 88.
    Nestola P et al. (2015) Robust design of adenovirus purification by two-column, simulated moving-bed, size-exclusion chromatography. J Biotechnol 213:109–119CrossRefPubMedGoogle Scholar
  89. 89.
    Higashikawa F, Chang L (2001) Kinetic analyses of stability of simple and complex retroviral vectors. Virology 280(1):124–131CrossRefPubMedGoogle Scholar
  90. 90.
    Segura MM et al. (2005) A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnol Bioeng 90(4):391–404CrossRefPubMedGoogle Scholar
  91. 91.
    Negrete A, Pai A, Shiloach J (2014) Use of hollow fiber tangential flow filtration for the recovery and concentration of HIV virus-like particles produced in insect cells. J Virol Methods 195:240–246CrossRefPubMedGoogle Scholar
  92. 92.
    Nony P et al. (2003) Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles. J Virol 77(1):776–781PubMedCentralCrossRefPubMedGoogle Scholar
  93. 93.
    Chadeuf G et al. (2005) Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol Ther 12(4):744–753CrossRefPubMedGoogle Scholar
  94. 94.
    Wright JF (2014) Product-related impurities in clinical-grade recombinant AAV vectors: characterization and risk assessment. Biomedicines 2:80–97PubMedCentralCrossRefPubMedGoogle Scholar
  95. 95.
    Segura MM et al. (2008) Identification of host proteins associated with retroviral vector particles by proteomic analysis of highly purified vector preparations. J Virol 82(3):1107–1117CrossRefPubMedGoogle Scholar
  96. 96.
    Denard J et al. (2009) Quantitative proteomic analysis of lentiviral vectors using 2-DE. Proteomics 9(14):3666–3676CrossRefPubMedGoogle Scholar
  97. 97.
    Qu G et al. (2007) Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J Virol Methods 140(1-2):183–192CrossRefPubMedGoogle Scholar
  98. 98.
    Lock M, Alvira MR, Wilson JM (2012) Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography. Hum Gene Ther Methods 23(1):56–64PubMedCentralCrossRefPubMedGoogle Scholar
  99. 99.
    Altaras NE et al. (2005) Production and formulation of adenovirus vectors. Adv Biochem Eng Biotechnol 99:193–260PubMedGoogle Scholar
  100. 100.
    Ayuso E et al. (2014) Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. Hum Gene Ther 25(11):977–987PubMedCentralCrossRefPubMedGoogle Scholar
  101. 101.
    Lock M et al. (2014) Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. Hum Gene Ther Methods 25(2):115–125CrossRefPubMedGoogle Scholar
  102. 102.
    Sommer JM et al. (2003) Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol Ther 7(1):122–128CrossRefPubMedGoogle Scholar
  103. 103.
    Shabram PW et al. (1997) Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 8(4):453–465CrossRefPubMedGoogle Scholar
  104. 104.
    Chosewood LC et al (2009) Biosafety in microbiological and biomedical laboratories, 5th edn. HHS Publication. U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health, Washington, DC, xxii, 415 ppGoogle Scholar
  105. 105.
    Norval GW (2015) Analysis of a blast due to inadvertant mixing of ammonium sulfate and sodium hypochlorite. Process Saf Prog 35:92CrossRefGoogle Scholar
  106. 106.
    Merten OW et al. (2014) Manufacturing of viral vectors: part II. Downstream processing and safety aspects. Pharm Bioprocess 2(3):237–251CrossRefGoogle Scholar
  107. 107.
    Nestola P et al. (2015) Improved virus purification processes for vaccines and gene therapy. Biotechnol Bioeng 112(5):843–857CrossRefPubMedGoogle Scholar
  108. 108.
    Genzel Y et al. (2014) High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells. Vaccine 32(24):2770–2781CrossRefPubMedGoogle Scholar
  109. 109.
    Vandenberghe LH et al. (2010) Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther 21(10):1251–1257PubMedCentralCrossRefPubMedGoogle Scholar
  110. 110.
    Rodrigues T et al. (2007) Scaleable purification process for gene therapy retroviral vectors. J Gene Med 9(4):233–243CrossRefPubMedGoogle Scholar
  111. 111.
    Reeves L, Cornetta K (2000) Clinical retroviral vector production: step filtration using clinically approved filters improves titers. Gene Ther 7(23):1993–1998CrossRefPubMedGoogle Scholar
  112. 112.
    Chahal PS, Aucoin MG, Kamen A (2007) Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system. J Virol Methods 139(1):61–70CrossRefPubMedGoogle Scholar
  113. 113.
    FDA (2010) Guidance for industry: characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indicationsGoogle Scholar
  114. 114.
    Shaw A et al. (2012) Using Pulmozyme DNase treatment in lentiviral vector production. Hum Gene Ther Methods 23(1):65–71PubMedCentralCrossRefPubMedGoogle Scholar
  115. 115.
    Schagen FH et al. (2000) Ammonium sulphate precipitation of recombinant adenovirus from culture medium: an easy method to increase the total virus yield. Gene Ther 7(18):1570–1574CrossRefPubMedGoogle Scholar
  116. 116.
    Wright JF, Wellman J, High KA (2010) Manufacturing and regulatory strategies for clinical AAV2-hRPE65. Curr Gene Ther 10(5):341–349CrossRefPubMedGoogle Scholar
  117. 117.
    Blom H et al. (2014) Efficient chromatographic reduction of ovalbumin for egg-based influenza virus purification. Vaccine 32(30):3721–3724CrossRefPubMedGoogle Scholar
  118. 118.
    Weigel T et al. (2014) A flow-through chromatography process for influenza A and B virus purification. J Virol Methods 207:45–53CrossRefPubMedGoogle Scholar
  119. 119.
    Lee J et al. (2012) Principles and applications of steric exclusion chromatography. J Chromatogr A 1270:162–170CrossRefPubMedGoogle Scholar
  120. 120.
    Nestola P et al. (2014) Adenovirus purification by two-column, size-exclusion, simulated countercurrent chromatography. J Chromatogr A 1347:111–121CrossRefPubMedGoogle Scholar
  121. 121.
    Strauss DM et al. (2009) Understanding the mechanism of virus removal by Q sepharose fast flow chromatography during the purification of CHO-cell derived biotherapeutics. Biotechnol Bioeng 104(2):371–380CrossRefPubMedGoogle Scholar
  122. 122.
    Auricchio A et al. (2001) A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol Ther 4(4):372–374CrossRefPubMedGoogle Scholar
  123. 123.
    Wisher M (2002) Biosafety and product release testing issues relevant to replication-competent oncolytic viruses. Cancer Gene Ther 9(12):1056–1061CrossRefPubMedGoogle Scholar
  124. 124.
    FDA (2006) Guidance for industry: supplemental guidance on testing for replication competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectorsGoogle Scholar
  125. 125.
    FDA (2010) November 19, 2010: Cellular, tissue and gene therapies advisory committee meeting, briefing document—testing for replication competent retrovirus (RCR)/Lentivirus (RCL) in retroviral and lentiviral vector based gene therapy products—revisiting current FDA recommendationsGoogle Scholar
  126. 126.
    Biosafety Considerations for Research with Lentiviral Vectors: Recombinant DNA Advisory Committee (RAC) Guidance Document, R.D.A. committee, Editor. 2006Google Scholar
  127. 127.
    Laboratory biosafety manual. 2004, World Health Organization, GenevaGoogle Scholar
  128. 128.
    Biosafety in Microbiological and Biomedical Laboratories, U.S.D.o.H.a.H. Services, Editor. 2007, U.S. Government Printing Office, Washington, DCGoogle Scholar
  129. 129.
    Tatalick LM et al. (2005) Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine. Vaccine 23(20):2628–2638CrossRefPubMedGoogle Scholar
  130. 130.
    Weaver B, Rosenthal S (2010) Viral risk mitigation for mammalian cell culture media. PDA J Pharm Sci Technol 64(5):436–439PubMedGoogle Scholar
  131. 131.
    Mann K et al. (2015) Protection of bioreactor culture from virus contamination by use of a virus barrier filter. BMC Proc 9(Suppl 9):1CrossRefGoogle Scholar
  132. 132.
    Hutchins B et al. (2000) Working toward an adenoviral vector testing standard. Mol Ther 2(6):532–534CrossRefPubMedGoogle Scholar
  133. 133.
    Lock M et al. (2010) Characterization of a recombinant adeno-associated virus type 2 reference standard material. Hum Gene Ther 21(10):1273–1285PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 2.5 International License (http://creativecommons.org/licenses/by-nc/2.5/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

Authors and Affiliations

  • Barb Thorne
    • 1
  • Ryan Takeya
    • 2
  • Francesca Vitelli
    • 3
  • Xin Swanson
    • 3
  1. 1.Thorne Bio-Consulting LLCSammamishUSA
  2. 2.RKT Bioconsulting, LLCLynnwoodUSA
  3. 3.Lonza Houston, Inc.HoustonUSA

Personalised recommendations